The Overactive Bladder Drug Market Will Increase From Approximately $3 Billion in 2009 to Nearly $4 Billion in 2019

Owing to a Meager Pipeline of Late-Stage Novel Agents, Considerable Untapped Opportunity Remains for Drug Development, According to Findings from Decision Resources

Oct 12, 2010, 08:00 ET from Decision Resources

BURLINGTON, Mass., Oct. 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that although more than 50 percent of people with overactive bladder (OAB) in the world's major pharmaceutical markets are undiagnosed, the sizeable prevalent population fuels significant sales for the indication. As a result, the OAB drug market will increase from approximately $3 billion in 2009 to nearly $4 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

The Pharmacor 2010 findings from the topic entitled Overactive Bladder reveal that the market is and will continue to be dominated by anticholinergics, but other classes such as beta3-adrenergic receptor agonists and neuromuscular-blocking agents will earn significant sales as they capitalize on the large segment of anticholinergic-refractory patients. Although selective oral anticholinergics, transdermal anticholinergics and the growing off-label use of Allergan's Botox have augmented the armamentarium of OAB treatment options, a sizeable percentage of OAB patients remain suboptimally served by existing drug therapies.

"Greater efficacy outweighs all other challenges in pharmacological management of overactive bladder," said Decision Resources Analyst Kyle Crowell. "An oral agent with a novel mechanism of action that reduces urinary frequency and/or episodes of incontinence by 25 to 50 percent compared with currently available anticholinergics would be well received in this market."

The Pharmacor 2010 findings also reveal that in the search for novel pharmacological approaches to OAB, many promising drug targets have resulted in developmental dead ends at the preclinical or clinical phase.

"As a result, the pipeline of late-stage novel agents for OAB is relatively meager, leaving considerable untapped opportunity for developers of agents with novel mechanisms of action," Mr. Crowell said.

About Pharmacor 2010

The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant disease topics.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:


Decision Resources, Inc.

Christopher Comfort

781-993-2597

ccomfort@dresources.com



SOURCE Decision Resources



RELATED LINKS

http://www.decisionresources.com